Alkermes (ALKS) Nears 52-Week High on Increasing Orexin Receptor Market Interest

Alkermes PLC (NASDAQ:ALKS) is one of the 10 Stocks Dominating Today’s Market Surge.

Alkermes extended gains for a second day on Tuesday to nearly hit its 52-week high, as investors digested the growing interest in the orexin receptor agonist market following a pharmaceutical giant’s official foray into the sector.

Weight loss drugmaker Eli Lilly and Company announced on the same day that it entered into a definitive agreement to acquire Centessa Pharmaceuticals—a clinical-stage company currently developing a pipeline of orexin receptor 2—for $6.3 billion.

The positive sentiment spilled over to Alkermes PLC (NASDAQ:ALKS), as Eli Lilly’s acquisition suggested a strong demand for the market.

Alkermes PLC (NASDAQ:ALKS) is likewise developing its own orexin 2 receptor agonists for other neurological disorders, including ADHD and fatigue associated with multiple sclerosis and Parkinson’s disease.

On the same day, its stock surged to a day high of $36.22, or just 10 cents shy of its 52-week high of $36.32, before paring gains to end the session just up by 17.28 percent at $35.36 apiece.

Last year, Alkermes PLC (NASDAQ:ALKS) saw its net income decline by 34 percent to $241.7 million from $367.1 million in 2024, while revenues dropped by 5 percent to $1.47 billion from $1.5 billion.

In the fourth quarter alone, net profit fell by 66 percent to $49.3 million from $146.5 million, while revenues decreased by 10.6 percent to $384.5 million from $430 million.

While we acknowledge the risk and potential of ALKS as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ALKS and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and 15 Stocks That Will Make You Rich in 10 Years.

Disclosure: None. Follow Insider Monkey on Google News.